KalVista launches EKTERLY after FDA approval, posts first sales but Q net loss widens

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) - quick read

What's happening inside the company
- FDA approved EKTERLY® (sebetralstat) on July 3, 2025; this is KalVista's first commercial product and the first oral on‑demand therapy for hereditary angioedema (HAE).
- Commercial launch in the U.S. began in July 2025 - first product revenue recorded for the quarter ended July 31, 2025.
- Company secured additional commercial/regional deals (Kaken: $11.0M non‑refundable upfront, recorded as deferred revenue) and regulatory momentum in EU/UK (MHRA approval; CHMP positive opinion; EC decision expected Oct 2025).
- Liquidity actions: royalty financing with DRI (upfront $100.0M in Nov 2024 plus $22.0M drawdown in Jul 2025), and an ATM facility up to $100.0M available with TD Cowen.

Key financial snapshot (as reported; amounts in thousands unless noted)
- Product revenue, net (3 months ended July 31, 2025): $1,426.
- Cost of revenue: $590.
- Research & development expense: $15,162 (down from $26,614 in prior-year quarter; decrease $11,452).
- Selling, general & administrative expense: $44,683 (up from $17,601; increase $27,082).
- Total operating expenses: $60,435 vs $44,215 prior year.
- Operating loss: $(59,009).
- Net loss: $(60,096) vs $(40,443) prior year; net loss per share: $(1.12).
- Weighted average shares outstanding: 53,497,128.
- Cash and cash equivalents: $124,304; Marketable securities: $67,161; combined cash + marketable securities ≈ $191,465 (reported as ~$191.5M in liquidity commentary).
- Accounts receivable, net: $1,926 (first post‑launch AR).
- Total assets: $215,505; Total stockholders' equity: $40,790; Accumulated deficit: $(713,266).
- Royalty obligation (net carrying amount after drawdown): $122,900; royalty obligation reported on balance sheet $132,321 (gross) with embedded derivative fair value $9,410.
- Net cash used in operating activities (Q): $(54,502); Net cash provided by investing: $21,261; financing: $23,210; net change in cash: $(7,308).
- Customer concentration (Q sales): Customer A 40%, Customer B 35%, Customer C 15% (three customers = 90% of gross product sales).

Positive aspects (income statement and operations)
- First product revenue recorded ($1,426) immediately after FDA approval - commercial launch started.
- R&D expense declined materially (from $26,614 to $15,162) reflecting transition from late‑stage development to commercialization - cash burn from R&D easing.
- Strong liquidity cushion from cash + marketable securities (~$191.5M), plus $22.0M DRI draw and $11.0M Kaken upfront; ATM capacity up to $100.0M provides optional financing runway.
- Regulatory progress outside the U.S. (MHRA approval; CHMP positive opinion) supports multi‑market commercial potential.

Negative aspects / risks (income statement and balance sheet)
- Big SG&A jump: $44,683 vs $17,601 prior year - commercialization costs drove operating loss higher and widened the net loss to $(60,096).
- Operating loss remains large: $(59,009) for the quarter - commercialization has not yet offset launch-related spending.
- Accumulated deficit deep at $(713,266) and shareholders' equity down to $40,790 - earnings erosion and dilution pressure remain risks.
- Heavy reliance on royalty financing: royalty obligation recorded $132,321 (embedded derivative $9,410). Associated interest expense ($3,522 interest expense in Q) and remeasurements add P&L volatility.
- Customer concentration in initial sales (40% and 35% for two customers) creates collections and revenue volatility risk.
- Net cash used in operating activities remains high $(54,502) - company will likely need to access capital as commercialization ramps if product revenue growth lags expectations.

Near‑term catalysts and watch‑items
- EKTERLY U.S. commercial uptake (sequential revenue growth and gross margin improvement).
- European Commission decision (expected Oct 2025) and execution of Kaken commercial milestones in Japan (royalties/milestones).
- Royalty obligation servicing and the effect of sales on the effective interest rate / amortization - sales forecasts materially impact future interest expense and payoff timeline.
- Customer diversification beyond the three initial large buyers and inventory/chargeback reserve development as sales scale.
- Cash runway vs. burn: monitor quarterly operating cash used vs revenue growth and any ATM or equity raises.

Bottom line: KalVista (NASDAQ: KALV) has moved from development to commercial stage with FDA approval and initial U.S. sales of EKTERLY. That unlocks revenue potential and reduces pure R&D burn, but launch costs (SG&A) and financing obligations (royalty liability and embedded derivative) pushed the quarter's net loss to $(60.1M) and generated significant operating cash outflow. The next few quarters will be decisive: growing product revenue and diversifying customers are required to convert regulatory wins into sustainable cash generation.